Don’t miss – Page 163 – Endpoints News

SIGN UP

Endpoints News ranks the top 57 players in the Covid-19 vaccine race. Here's how it stacks up today

3 years ago

Covid-19 roundup: Pfizer-backed BioNTech plans to seek FDA OK for a new vaccine 'as early as' October — ahead of the election

3 years ago

Hunting a blockbuster, Bayer forges an $875M-plus M&A deal to acquire women’s health biotech

3 years ago

Innovent and Eli Lilly challenge Merck's mega-blockbuster Keytruda in non-small cell lung cancer field

3 years ago

Spark Therapeutics nabs new CMO from Genentech, filling a major post-merger departure

3 years ago

Covid-19 roundup: CureVac beefs up its unicorn IPO dreams as billionaire owner takes this Covid-19 mRNA player on a forced march to Nasdaq; Kodak's $765M deal is put on hold

3 years ago

After a 4-year sojourn, struggling microbiome pioneer Seres claims a breakout PhIII comeback. And shares respond in frenzied spike

3 years ago

Biogen scores a priority review for its Alzheimer's drug aducanumab, moving one giant leap forward in its controversial quest

3 years ago

Covid-19 roundup: Gates Foundation pours $150M into India’s Serum Institute; Pfizer teams with Gilead on remdesivir

3 years ago

'October is coming,' and everyone still wants to know if a Covid-19 vaccine will be whisked through the FDA ahead of the election

3 years ago

Alnylam president Barry Greene leaves after 17 years, handing position over to Yvonne Greenstreet as biotech looks toward profitability

3 years ago

Biogen hands Denali $1B-plus in cash, $1B-plus in milestones to partner on late-stage Parkinson’s drug

3 years ago

Covid-19 roundup: 34 AGs call for ‘march-in’ rights on remdesivir; Hahn pleads with public to trust FDA's vaccine review

3 years ago

Roche-backed Dicerna pushes into the pack racing toward the blockbuster hep B goal line, armed with PhI data

3 years ago

Lundbeck sounds taps on another CNS drug, retreating from a mine field still occupied by a Merck team

3 years ago

Moderna CEO Stéphane Bancel outlines a prospective motherlode of Covid-19 vaccine revenue — will a backlash follow?

3 years ago

Covid-19 roundup: J&J and BARDA agree to $1 billion for 100 million doses; Plasma reduces mortality by 50% — reports

3 years ago

Novavax heralds the latest positive snapshot of early-stage Covid-19 vaccine — so why did its stock briefly crater?

3 years ago

CureVac nabs a top Novartis scientist for CSO slot as mRNA vaccines seize the spotlight

3 years ago

OWS' Moncef Slaoui lambasts ‘insulting’ media coverage: 'How are you helping in this pandemic?'

3 years ago

When will it end? Goldman economist gives late-stage vaccines a good shot at targeting 'large shares' of the US by mid-2021 — but the downside is daunting

3 years ago

J&J gets a fresh OK for esketamine, but is it really the game-changer for depression Trump keeps tweeting about?

3 years ago

Sanofi and GSK say they're near a vaccine deal with EU hours after finalizing Warp Speed contract

3 years ago

Trump’s ‘radical’, ‘horrible’ executive orders on drug pricing earn a C-suite backlash this week — with one threat to do more overseas

3 years ago

First page Previous page 160 161 162163164 165 166 Next page Last page